Physician profile
Lars D Thompson
NPI 1063511772
$4,551.65
in general payments reported to CMS, 2019-2025
27 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $783 · 2021: $456 · 2022: $816 · 2023: $650 · 2024: $451 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $780.80 | 2019-2025 | |
| Pfizer INC. | $688.86 | 2019-2025 | |
| Astellas Pharma US INC | $505.24 | 2019-2025 | Xtandi |
| Abbvie INC. | $480.59 | 2019-2025 | Botox, Lupron Depot |
| Janssen Biotech, INC. | $303.41 | 2019-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $278.44 | 2019-2025 | Provenge |
| Neotract INC. | $250.95 | 2019-2020 | |
| Teleflex LLC | $203.07 | 2021-2024 | Urolift |
| Accord Healthcare, INC. | $128.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $120.41 | 2025 | |
| Sumitomo Pharma America, INC. | $106.40 | 2023-2025 | Orgovyx, Gemtesa |
| Endo USA, INC. | $95.58 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $91.42 | 2019-2025 | Adstiladrin |
| Telix Pharmaceuticals | $80.48 | 2025 | Illuccix |
| 180 Medical, INC. | $73.25 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $60.41 | 2022 | |
| Merck Sharp & Dohme LLC | $53.89 | 2019-2023 | Lynparza, Keytruda |
| Myovant Sciences INC. | $46.38 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.34 | 2022 | |
| Olympus America INC. | $36.17 | 2025 | Olympus, Bovie, Hd Camera Head |
| Tolmar Pharmaceuticals, INC. | $21.11 | 2020 | |
| Endo Pharmaceuticals INC. | $20.79 | 2020 | |
| Boston Scientific Corporation | $19.85 | 2019 | |
| Medtronic, INC. | $19.84 | 2025 | Altaviva |
| Smith+Nephew, INC. | $19.24 | 2022 | |
| Coloplast Corp | $15.34 | 2023 | Speedicath |
| Astrazeneca Pharmaceuticals Lp | $13.91 | 2024 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lars Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.